Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
243.00
-4.00 (-1.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Alnylam Shares Shoot Higher Following Positive Clinical Results From Late-Stage ATTR Amyloidosis Therapeutics
August 03, 2022
Alnylam (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why
August 03, 2022
Alnylam stock is on track to open at a record high Wednesday after its cardiomyopathy drug met every goal in a final-phase study.
Via
Investor's Business Daily
Why Alnylam Pharma Shares Are Trading Higher During Premarket Session
August 03, 2022
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) shares are rallying after upbeat data from APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Via
Benzinga
Expert Ratings for Alnylam Pharmaceuticals
July 15, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
June 07, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 03, 2022
Via
Benzinga
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
August 03, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
August 02, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
July 28, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Alnylam Pharmaceuticals: Q2 Earnings Insights
July 28, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q2 earnings results on Thursday, July 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
July 28, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
July 27, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform
July 25, 2022
Via
Benzinga
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
July 18, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine
July 15, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
July 13, 2022
Upgrades
Via
Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 06, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 05, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
5 Best And Worst Performing Large-Cap Stocks In June 2022
July 05, 2022
Over the past decade or so, these large-cap stocks have outperformed their smaller peers. Let’s take a look at the five best and worst performing large-cap stocks in June 2022.
Via
Talk Markets
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
June 27, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
June 27, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
June 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate
June 13, 2022
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary...
Via
Benzinga
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
June 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
June 09, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
June 07, 2022
Upgrades
Via
Benzinga
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
June 02, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.